Clinical Trials Logo

Varicella Zoster Virus Infection clinical trials

View clinical trials related to Varicella Zoster Virus Infection.

Filter by:

NCT ID: NCT01682109 Completed - Clinical trials for Varicella Zoster Virus Infection

Palatability Testing of a New Paediatric Formulation of Valacyclovir

VALID-0
Start date: September 2012
Phase: Phase 4
Study type: Interventional

Palatability testing of a new paediatric formulation of valacyclovir in children 4-12 years of age and at least one of their parents. Children will be included, who received (val)acyclovir prophylaxis in the past, or will probably need it in the future i.e. children with primary immune deficiency or cancer.

NCT ID: NCT01506661 Completed - Clinical trials for Rheumatoid Arthritis

Safety of Zostavax Vaccination in Rheumatoid Arthritis

Start date: January 2012
Phase: Phase 1
Study type: Interventional

Herpes Zoster (shingles) is caused by reactivation of latent varicella zoster virus (VZV) that usually occurs decades following initial exposure. The risk of developing shingles increases with age. Shingles presents as a painful, itchy blistering rash that usually involves a single portion of the skin and lasts about 7-10 days. The risk of developing shingles increases with age in healthy people, and has been shown in some studies to be increased in people with rheumatoid arthritis and other autoimmune diseases. Zostavax, a live-attenuated vaccine against the varicella zoster virus, was first approved by the FDA for the prevention of Shingles among people 60 years and older, and is now approved for use in people aged 50 years and older. Because rheumatoid arthritis and some of the medications used to treat rheumatoid arthritis can impair the body's immune system, it is not known how much of an immune response can be generated in people with rheumatoid arthritis. The goals of this study are to measure the immune response after standard vaccination with Zostavax in people with rheumatoid arthritis in comparison to people with healthy immune systems. All participants will be 50 years old or older, and subjects with rheumatoid arthritis will not be eligible if they are taking certain biologic medications, including TNF inhibitors (Etanercept or Adalimumab). Ten healthy subjects and 10 subjects with rheumatoid arthritis will all receive a single vaccination with Zostavax, then will be followed for 12 weeks to assess the immune response and for the development of local rash or other potential side effects.

NCT ID: NCT01138215 Completed - HIV Infections Clinical Trials

The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children

Start date: June 2009
Phase: Phase 4
Study type: Interventional

To study about the immunogenicity, safety and efficacy of varicella-zoster virus vaccine in HIV-infected children.